TY - JOUR
T1 - Comparative effectiveness of four COVID-19 vaccines, BNT162b2 mRNA, mRNA-1273, ChAdOx1 nCov-19 and NVX-CoV2373 against SARS-CoV-2 B.1.1.529 (Omicron) infection
AU - Liu, Bette
AU - Stepien, Sandrine
AU - Qian, Jiahui
AU - Gidding, Heather
AU - Nicolopoulos, Katrina
AU - Amin, Janaki
AU - Cheng, Allen
AU - Macartney, Kristine
N1 - Funding Information:
Supported by NSW Ministry of Health.
Funding Information:
We thank colleagues at NSW Health for their support and access to data and to the NSW Centre for Health Record Linkage for conducting the linkage.
Publisher Copyright:
© 2023 Elsevier Ltd
PY - 2023/8/31
Y1 - 2023/8/31
N2 - Background: There is limited data directly comparing the effectiveness of different COVID-19 vaccines. Methods: We compared rates of SARS-CoV-2 Omicron BA.1/2 infection during March to May 2022 in Australian adults who had received one of four COVID-19 vaccines in the last 14–63 days as either a primary course or a booster dose using Cox proportional hazards models adjusting for age and other characteristics. Results: As a primary course, over 2318 person-years and 1033 infections, compared to recipients of BNT162b2 mRNA vaccine, adjusted hazard ratios for SARS-CoV-2 infection were 1.03 (95%CI 0.82–1.30), 1.19 (0.95–1.49), 1.70 (1.46–1.97) for respectively mRNA-1273, ChAdOx-1 nCov-19 and NVX-CoV2373. For the booster dose, over 154,984 person-years and 93,580 infections the respective adjusted hazard ratios compared to BNT162b2 mRNA vaccine were 1.02 (95%CI 1.00–1.04), 1.20 (1.10–1.32), 1.39 (1.20–1.60). Conclusions: Our findings suggest relatively higher effectiveness of ancestral strain mRNA vaccines against SARS-CoV-2 Omicron infection than viral vector and protein subunit vaccines and provide clinical confirmation of immunological data on differences in COVID-19 vaccine performance.
AB - Background: There is limited data directly comparing the effectiveness of different COVID-19 vaccines. Methods: We compared rates of SARS-CoV-2 Omicron BA.1/2 infection during March to May 2022 in Australian adults who had received one of four COVID-19 vaccines in the last 14–63 days as either a primary course or a booster dose using Cox proportional hazards models adjusting for age and other characteristics. Results: As a primary course, over 2318 person-years and 1033 infections, compared to recipients of BNT162b2 mRNA vaccine, adjusted hazard ratios for SARS-CoV-2 infection were 1.03 (95%CI 0.82–1.30), 1.19 (0.95–1.49), 1.70 (1.46–1.97) for respectively mRNA-1273, ChAdOx-1 nCov-19 and NVX-CoV2373. For the booster dose, over 154,984 person-years and 93,580 infections the respective adjusted hazard ratios compared to BNT162b2 mRNA vaccine were 1.02 (95%CI 1.00–1.04), 1.20 (1.10–1.32), 1.39 (1.20–1.60). Conclusions: Our findings suggest relatively higher effectiveness of ancestral strain mRNA vaccines against SARS-CoV-2 Omicron infection than viral vector and protein subunit vaccines and provide clinical confirmation of immunological data on differences in COVID-19 vaccine performance.
UR - http://www.scopus.com/inward/record.url?scp=85166327649&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2023.07.050
DO - 10.1016/j.vaccine.2023.07.050
M3 - Article
C2 - 37524631
AN - SCOPUS:85166327649
SN - 0264-410X
VL - 41
SP - 5587
EP - 5591
JO - Vaccine
JF - Vaccine
IS - 38
ER -
